Release Date: 15-Jul-2024
In the realm of cancer therapeutics, MCLA-129 emerges as a novel and promising candidate, developed by Merus to address solid cancers. This human, EGFR/c-MET Biclonic bispecific antibody boasts a unique design, incorporating two complementary mechanisms of action. Its dual-pronged approach positions MCLA-129 as a versatile and potentially potent tool in the ongoing quest for effective treatments against solid cancers.
MCLA-129 is a potent therapeutic designed to target the HGF/c-MET pathway, commonly upregulated in cancers resistant to EGFR tyrosine kinase inhibitors. It addresses both EGFR and c-MET in non-small cell lung cancer (NSCLC) and other solid cancers through antibody-dependent cellular cytotoxicity (ADCC). By inhibiting tumor growth through reduced ligand-dependent phosphorylation of EGFR and c-MET, MCLA-129 employs a multimodal mechanism that includes suppressing c-MET and EGFR signaling, and enhancing antibody-dependent cellular phagocytosis (ADCP) and ADCC. This comprehensive approach positions MCLA-129 as a promising option to disrupt critical pathways in tumor development and progression.
In in vivo studies, MCLA-129 proved to be a potent inhibitor of tumor growth, showing dose-dependent efficacy in various non-small cell lung cancer (NSCLC) models, including an EGFR exon20ins patient-derived NSCLC xenograft model. Its inhibitory effects extend to c-MET and EGFR ligand binding, highlighting its multifaceted action. Additionally, MCLA-129 exhibits antibody-dependent cellular phagocytosis (ADCP) and antibody-dependent cellular cytotoxicity (ADCC), demonstrating comparable or superior potency compared to amivantamab. These findings underscore MCLA-129’s potential as a versatile therapeutic option in NSCLC and other solid tumors.
Merus is currently overseeing multiple early-phase clinical trials assessing MCLA-129 in diverse solid cancers, such as non-small cell lung cancer, head and neck cancer, and colorectal cancer. Concurrently, its partner, Betta Pharmaceuticals, is conducting parallel trials in China under an exclusive license agreement established in 2019. A phase 1/2 trial investigating MCLA-129 as a monotherapy in solid tumors demonstrated favorable tolerability and a manageable safety profile. Encouragingly, antitumor activity was observed in heavily pretreated patients across various tumor types and dose levels.
In conclusion, MCLA-129 stands as a promising beacon in the field of cancer therapeutics, showing notable efficacy and a favorable safety profile in early-phase trials across various solid cancers. The encouraging antitumor activity observed in heavily pretreated patients underscores its potential as a valuable treatment option. With ongoing trials exploring its efficacy as a monotherapy and in combination with chemotherapy, MCLA-129 holds promise for reshaping the landscape of cancer treatment.
For Clinical Trials Information Contact [email protected]